Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 15/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.48 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833866 | 0.91 | ITGAV (0.56) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL30336058 | 0.91 | ITGAV (0.56) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL12807006 | 0.89 | ITGAV (0.58) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL21766819 | 0.88 | ITGAV (0.60) | ITGAVITGB3ITGB5ITGB6 | |
| SCHEMBL12895016 | 0.87 | ITGAV (0.47) | ITGAVITGB3ITGB5CXCR4ITGB6 | |
| SCHEMBL4718031 | 0.86 | ITGAV (0.51) | ITGAVITGB3ITGB5CXCR4ITGB6 | |
| SCHEMBL4714404 | 0.85 | ITGB3 (0.52) | ITGAVITGB3ITGB5CXCR4ITGB6 | |
| SCHEMBL1827947 | 0.85 | ITGAV (0.54) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL23426185 | 0.84 | ITGAV (0.51) | ITGAVITGB3ITGB5CXCR4ITGB6 | |
| SCHEMBL5849898 | 0.84 | ITGB3 (0.51) | ITGAVITGB3ITGB5CXCR4ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3908288-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3784269-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | Arrowhead Pharmaceuticals, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2020210404-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089357-A1 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018049068-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-6881736-B1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | ITGAV 1/4885ITGB3 3/4885ITGB5 4/4885 |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | ITGAV 1/4885ITGB3 3/4885ITGB5 4/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | ITGAV 3/4885ITGB3 1/4885ITGB5 5/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ITGAV 2679/4885ITGB3 2099/4885ITGB5 1137/4885 |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | ITGAV, ITGB1, ITGB3 | ITGAV 1/4885ITGB3 3/4885ITGB5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.